Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.68 |
| ▸ | BCHE | P06276 | 8/20 | 0.66 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411728 | 1.00 | MAOB (0.68) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL1775149 | 0.89 | MAOB (0.58) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL4825449 | 0.86 | MEN1 (0.58) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL21429714 | 0.86 | MAOB (0.55) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL4158572 | 0.86 | MAOB (0.69) | MAOBBCHEMAOANR4A2 | |
| SCHEMBL15761340 | 0.86 | BCHE (0.70) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL1268719 | 0.86 | MAOB (0.81) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL9707070 | 0.85 | FFAR1 (0.59) | MAOBBCHECYP4F2CYP4A11LCK | |
| SCHEMBL27733468 | 0.85 | CYP4F2 (0.70) | MAOBBCHECYP4F2CYP4A11MAOA | |
| SCHEMBL5027658 | 0.85 | MEN1 (0.56) | MAOBBCHECYP4F2CYP4A11MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115959962-B | Visible light-promoted halogenated alkane hydrodehalogenation method | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | claimed |
| CN-115850002-B | Method for hydrodehalogenating halogenated alkane | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | claimed |
| CN-119101052-A | Matrine-triazole derivative and synthesis method thereof | 吉林医药学院 | 2024-12-10 | — | — | CN | claimed |
| EP-4711355-A1 | CRYSTAL FORM OF LIPOPROTEIN COMPOUND AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-12459895-B2 | MEK inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | TAXIS PHARMACEUTICALS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-115959962-B | Visible light-promoted halogenated alkane hydrodehalogenation method | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | disclosed |
| CN-115850002-B | Method for hydrodehalogenating halogenated alkane | 中国科学院兰州化学物理研究所 | 2025-05-23 | — | — | CN | disclosed |
| WO-1995000146-A1 | AMINO BI- AND TRI-CARBOCYCLIC ALKANE BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-01-05 | — | — | WO | disclosed |
| WO-1994027601-A1 | ALIPHATIC AMINO BIS-ARYL SQUALENE SYNTHASE INHIBITORS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1992015579-A1 | MULTICYCLIC TERTIARY AMINE POLYAROMATIC SQUALENE SYNTHETASE INHIBITORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-09-17 | — | — | WO | disclosed |
| EP-0434365-A2 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1991-06-26 | — | — | EP | disclosed |
| US-4347375-A | Process for preparing amino acids and esters | MERCK & CO., INC. (US) | 1982-08-31 | — | — | US | disclosed |
| EP-0007615-B1 | PROCESS FOR PREPARING AMINO ACIDS AND ESTERS | MERCK & CO. INC. (US) | 1982-06-16 | — | — | EP | disclosed |
| US-4275220-A | N-(BENZYLIDENE OR ALKYLIDENE)-2-AMINOCROTONATE CHEMICAL INTERMEDIATE | MERCK & CO., INC. (US) | 1981-06-23 | — | — | US | disclosed |
| EP-0008657-A1 | Alpha-vinyl-alpha-aminoacids and their esters and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1980-03-19 | — | — | EP | disclosed |
| EP-0007615-A2 | Process for preparing amino acids and esters | MERCK & CO. INC. (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | MAOB 958/4885BCHE 1315/4885CYP4F2 445/4885 |
| US-12459895-B2 | MEK inhibitors and uses thereof | BRAF, NRAS, KRAS | MAOB 3464/4885BCHE 4050/4885CYP4F2 3669/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | MAOB 2823/4885BCHE 4269/4885CYP4F2 4594/4885 |
| US-20250179008-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | MAOB 604/4885BCHE 2575/4885CYP4F2 1153/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | MAOB 3262/4885BCHE 4304/4885CYP4F2 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.